EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Quantitation of Cirtuvivint (SM08502) in Human Plasma by LC–MS/MS

Julianne L Holleran, Joshua J Deppas iD, Ye Feng, Michael J Hochman iD, Evan C Chen, Maximilian Stahl iD, Steven D Gore, Timothy W Synold iD, Jan H Beumer iD, Raman Venkataramanan iD, Robert A Parise iD

Biomedical Chromatography · 2026-10 · 40 (10)

DOI: 10.1002/bmc.70565 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomedical Chromatography, online erschienen am 18.08.2026. Verfasst von Julianne L Holleran und 10 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA. Hauptthemen laut MEDLINE: Tandem Mass Spectrometry, Liquid Chromatography-Mass Spectrometry, Protein Kinase Inhibitors. Die Arbeit nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: U.S. Department of Defense, NCI NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CDC‐like kinases (CLK) and dual‐specificity tyrosine‐regulated kinases (DYRK) are protein kinases involved in various cellular functions, mRNA splicing, and DNA damage repair. CLK/DYRK kinases have been implicated in many disorders such as diabetes, neurodegenerative diseases, and cancer. Cirtuvivint (SM08502) is an orally bioavailable, first‐in‐class pan‐CLK and pan‐DYRK inhibitor that modulates pre‐mRNA splicing and has shown the ability to inhibit cancer cell growth in vitro and reduce tumor burden in vivo. This has led to the administration of cirtuvivint in phase I clinical trials. To quantitate cirtuvivint, we have developed and validated an LC–MS/MS method in human plasma. The assay is simple and robust and consists of a protein precipitation, dilute‐and‐shoot extraction method using 20 μL of plasma, chromatographic separation with a Phenomenex Kinetex C18, and a gradient mobile phase system consisting of 0.1% formic acid in water and acetonitrile. The chromatographic method is followed by mass spectrometric detection with a SCIEX 4500 tandem mass spectrometer. The method has a 5‐min run time and is linear from 5 to 1000 ng/mL. The assay met the criteria outlined by the US Food and Drug Administration guidance for bioanalytical method validation and will support ongoing and future clinical studies defining cirtuvivint pharmacokinetics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tandem Mass SpectrometryLiquid Chromatography-Mass SpectrometryProtein Kinase InhibitorsHumansReproducibility of ResultsLinear ModelsLimit of DetectionProtein Serine-Threonine Kinases

Stichwörter der Autor:innen

LC–MS/MSSM08505cirtuvivinthuman plasmapharmacokineticsvalidation

Substanzen

Protein Kinase InhibitorsProtein Serine-Threonine Kinases

Autor:innen und Institutionen

  • Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
  • Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California, USA.
  • Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.
  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Department of Internal Medicine, Section of Medical Oncology and Hematology, Yale University School of Medicine and Yale Comprehensive Cancer Center, New Haven, Connecticut, USA.

ORCID-Profile: Joshua J Deppas, Michael J Hochman, Maximilian Stahl, Timothy W Synold, Jan H Beumer, Raman Venkataramanan, Robert A Parise

Förderung

  • U.S. Department of Defense
  • NCI NIH HHS
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Holleran, J. L., Deppas, J. J., Feng, Y., Hochman, M. J., Chen, E. C., Stahl, M., Gore, S. D., Synold, T. W., Beumer, J. H., Venkataramanan, R., & Parise, R. A. (2026). Quantitation of Cirtuvivint (SM08502) in Human Plasma by LC–MS/MS. Biomedical Chromatography, 40(10). https://doi.org/10.1002/bmc.70565

Vancouver

Holleran JL, Deppas JJ, Feng Y, Hochman MJ, Chen EC, Stahl M, et al. Quantitation of Cirtuvivint (SM08502) in Human Plasma by LC–MS/MS. Biomedical Chromatography. 2026;40(10). doi:10.1002/bmc.70565

BibTeX
@article{Holleran2026,
  author = {Holleran, Julianne L and Deppas, Joshua J and Feng, Ye and Hochman, Michael J and Chen, Evan C and Stahl, Maximilian and Gore, Steven D and Synold, Timothy W and Beumer, Jan H and Venkataramanan, Raman and Parise, Robert A},
  title = {Quantitation of Cirtuvivint (SM08502) in Human Plasma by LC–MS/MS},
  journal = {Biomedical Chromatography},
  year = {2026},
  volume = {40},
  number = {10},
  doi = {10.1002/bmc.70565}
}
Kostenlos starten →